The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwCLL 2019 | MRD: a prognostic marker in targeted therapy
Talha Munir, MBBS, Leeds Teaching Hospitals NHS Trust, Leeds, UK discusses the role of minimal residual disease (MRD) in the new era of targeted drugs. Munir refers to three trials: MURANO, CLL14 and CLARITY (ISCRTN13751862, NCT02005471, NCT02242942), with regards to how measurable residual disease (MRD) is being used to personalize treatment and predict response. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.
